Evidence map›Paper›PMID 39576749›Full record

ReviewThe Journal of physiology2025

Incretin hormones and obesity.

Constanza Alcaino, Frank Reimann, Fiona M Gribble

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Incretin polyagonists as an alternative to bariatric surgery to manage obesity.World journal of gastrointestinal pathophysiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Constanza AlcainoInstitute of Metabolic Science Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0001-9595-4330
Frank ReimannInstitute of Metabolic Science Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Fiona M GribbleInstitute of Metabolic Science Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0002-4232-2898

Funding

Medical Research Council MC_UU_12012/3UKRI | Medical Research Council (MRC) MRC_MC_UU_12012/3Wellcome Trust 220271Wellcome Trust (WT) 220271/Z/20/Z
6 · The paper itself

Abstract

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) play critical roles in co-ordinating postprandial metabolism, including modulation of insulin secretion and food intake. They are secreted from enteroendocrine cells in the intestinal epithelium following food ingestion, and act at multiple target sites including pancreatic islets and the brain. With the recent development of agonists targeting GLP-1 and GIP receptors for the treatment of type 2 diabetes and obesity, and the ongoing development of new incretin-based drugs with improved efficacy, there is great interest in understanding the physiology and pharmacology of these hormones.

Indexed as

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsObesityAnimalsHumansGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsenteroendocrineGIPGLP‐1gut hormoneincretinobesity

Identifiers

PMID39576749
PMCPMC7617301

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.